查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1662670

預測和預後測試市場預測至 2030 年：按類型、適應症、技術、樣本、最終用戶和地區進行的全球分析

Predictive Presymptomatic Testing Market Forecasts to 2030 - Global Analysis By Type (Genetic Testing, Biochemical Testing, Molecular Testing and Other Types), Indication, Technology, Sample, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球預測和預測測試市場預計在 2024 年將達到 56 億美元，到 2030 年將達到 109 億美元，預測期內的複合年成長率為 11.6%。預測和預後測試是一種遺傳方法，用於在症狀出現之前識別有患上某些遺傳疾病風險的個體。透過分析 DNA 來檢測與特定疾病相關的突變和標記，例如亨廷頓氏舞蹈症、某些癌症、心血管和神經退化性疾病。該測試將評估未來患有該疾病的可能性，以便採取改變生活方式和加強監測系統等預防措施。

根據2021年發表在Frontiers上的一篇論文，日本罕見遺傳疾病的發生率不到每2500人中的1人。

提高對遺傳疾病的認知與發病率

隨著越來越多人意識到自己的遺傳傾向，對早期檢測以便及時介入的需求也日益成長。癌症、心血管疾病和神經系統疾病等遺傳疾病的發生率不斷上升，進一步增加了預測檢測的需求。旨在提高遺傳素養的政府措施和公共衛生宣傳活動也促進了市場的成長。此外，預防性醫療保健實踐的日益普及也推動了全球範圍內預測性測試的採用。

道德和心理問題

許多人擔心了解自己的遺傳風險會帶來潛在的心理負擔，這會導致焦慮和壓力。道德困境，包括保險公司和雇主可能濫用基因訊息，也對市場成長構成了挑戰。此外，對測試結果的準確性以及假陽性和假陰性的影響的擔憂也加劇了人們的猶豫。圍繞遺傳疾病的文化和社會恥辱進一步限制了此類測試的採用並阻礙了市場成長。

基因檢測技術的進展

下一代定序 (NGS) 和基於 CRISPR 的技術等創新正在提高基因檢測的準確性、速度和可負擔性。這些技術使得與遺傳疾病相關的遺傳變異的分析成為可能，從而實現了個人化的風險評估。人工智慧（AI）和巨量資料分析的整合進一步支持了預測模型並提高了測試的臨床效用。此外，直接面對消費者的基因檢測套組的開發將擴大基因檢測的管道，為市場成長開闢新的途徑。

對準確性和可靠性的擔憂

由於檢測機構的檢測方法和標準不同，檢測結果也存在差異，削弱消費者信心。假陽性和假陰性可能導致不適當的醫療決策，進一步影響患者的結果。缺乏通用的基因檢測法律規範加劇了這些挑戰，並造成了不同地區檢測品質的差異。此外，解釋遺傳資料的複雜性需要專業知識，而這並不總是存在的。總的來說，這些因素威脅著市場的成長潛力，並凸顯了強而有力的品質保證措施的必要性。

COVID-19 的影響

COVID-19 疫情對預測測試市場產生了重大影響。一方面，衛生系統和診斷服務的中斷減慢了檢測程序並減少了患者接受常規篩檢的機會。另一方面，這場疫情凸顯了預防醫學的重要性，並激發了人們對透過基因檢測早期發現疾病的興趣。隨著世界進入後疫情時代，市場因重新關注預防性醫療措施而有望復甦和成長。

預測期內，基因檢測市場規模預計將達到最大

由於對遺傳疾病的早期診斷和干涉，預計基因檢測領域將在預測期內佔據最大的市場佔有率。技術進步和對遺傳風險認知的提高正在促進這些測試的採用。此外，基於唾液的基因測試等非侵入性測試方法的出現，使得預測預後測試變得更容易取得且更經濟實惠。

在預計預測期內，次世代定序 (NGS) 領域將以最高的複合年成長率成長。

由於基因組醫學的快速發展和遺傳疾病發病率的上升，預計次世代定序 (NGS) 領域將在預測期內呈現最高的成長率。這部分包括一系列受益於早期發現和早期療育的疾病的測試，包括癌症、心血管疾病和神經系統疾病。價格實惠的基因檢測選項的不斷增加也有望推動該領域的顯著成長。

比最大的地區

預計北美將在預測期內佔據最大的市場佔有率，這得益於其完善的醫療保健基礎設施，以及由於越來越多的個人尋求個性化醫療並提高對個性化醫療的認知而對基因檢測的高需求。此外，主要研究機構和專門從事基因檢測技術的生物技術公司的存在有助於北美市場佔有率。政府推動基因素養和個人化醫療的舉措也有望在幫助北美繼續引領市場方面發揮關鍵作用。

複合年成長率最高的地區

在預測期內，由於醫療保健基礎設施的進步、可支配收入的增加以及對預防性醫療保健的日益重視，預計亞太地區將呈現最高的複合年成長率。此外，在政府投資和私營部門舉措的推動下，中國和印度等國家的基因研究和檢測能力正在顯著成長。隨著人們對遺傳疾病和基因檢測意識的提高，該地區對預測檢測的需求可能會激增，特別是在擁有最先進醫療服務的都市區。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章 全球預測與預測測驗市場按類型分類

  • 介紹
  • 基因檢測
    • 單基因檢測
    • 全基因組序列分析
    • 全EXOME定序
  • 生物化學檢驗
  • 分子檢測
  • 其他

6. 全球預測與預後測試市場（依適應症分類）

  • 介紹
  • 腫瘤學
  • 神經系統疾病
  • 心血管疾病
  • 內分泌失調
  • 遺傳性疾病
  • 其他

7. 全球預測與預測測試市場（按技術分類）

  • 介紹
  • 新一代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 微陣列技術
  • 螢光原位雜合反應（FISH）
  • 其他

第 8 章。

  • 介紹
  • 血
  • 唾液
  • 組織切片檢查
  • 其他範例

第9章。

  • 介紹
  • 醫院
  • 診斷實驗室
  • 研究和學術機構
  • 專科門診
  • 其他

第 10 章。

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • 23andMe
  • Abbott Laboratories Inc.
  • Quest Diagnostics Inc.
  • Positive Bioscience
  • Color Genomics
  • Gene by Gene
  • Mapmygenome
  • Myriad Genetics
  • BioAxis DNA Research Center Private Limited
  • Direct Laboratory Services LLC
  • Pathway Genomics Corporation
  • Ambry Genetics Corporation
  • Akonni Biosystems
  • Element Biosciences
  • Eurofins Scientific
  • NGeneBio
Product Code: SMRC28531

According to Stratistics MRC, the Global Predictive Presymptomatic Testing Market is accounted for $5.6 billion in 2024 and is expected to reach $10.9 billion by 2030 growing at a CAGR of 11.6% during the forecast period. Predictive presymptomatic testing is a genetic method used to identify individuals at risk of developing a specific hereditary condition before symptoms appear. It analyzes DNA to detect mutations or markers associated with certain diseases, such as Huntington's disease, certain cancers, and cardiovascular or neurodegenerative disorders. This testing estimates the likelihood of developing a condition in the future; enabling proactive measures like lifestyle changes and increased surveillance.

According to the article published by Frontiers in 2021, in Japan, the rare hereditary disease prevalence was equivalent to less than 1 in 2,500 people.

Market Dynamics:

Driver:

Increasing awareness and incidence of hereditary diseases

As more individuals become aware of their genetic predispositions, there is a growing demand for early testing to enable timely interventions. The increasing prevalence of hereditary conditions such as cancer, cardiovascular diseases, and neurological disorders has further amplified the need for predictive testing. Government initiatives and public health campaigns aimed at promoting genetic literacy also contribute to market growth. Additionally, the growing acceptance of preventive healthcare practices is driving the adoption of predictive presymptomatic testing worldwide.

Restraint:

Ethical and psychological concerns

Many individuals fear the potential psychological burden of knowing their genetic risks, which can lead to anxiety and stress. Ethical dilemmas, including the potential misuse of genetic information by insurers or employers, also pose challenges to market growth. Moreover, concerns about the accuracy of test results and the implications of false positives or negatives add to the hesitancy. Cultural and societal stigma around hereditary diseases further restricts the widespread adoption of these tests hampering the growth of the market.

Opportunity:

Advancements in genetic testing technologies

Innovations such as next-generation sequencing (NGS) and CRISPR-based techniques have enhanced the accuracy, speed, and affordability of genetic testing. These technologies enable comprehensive analysis of genetic variants associated with hereditary diseases, allowing for personalized risk assessment. The integration of artificial intelligence (AI) and big data analytics further supports predictive modeling and enhances the clinical utility of testing. The development of direct-to-consumer genetic testing kits also widens access, creating new avenues for market growth.

Threat:

Accuracy and reliability concerns

Variability in test results due to differences in testing methodologies and laboratory standards undermines consumer trust. False positives or negatives can lead to inappropriate medical decisions, further impacting patient outcomes. The lack of universal regulatory frameworks for genetic testing exacerbates these challenges, creating disparities in test quality across regions. Additionally, the complexity of interpreting genetic data requires specialized expertise, which may not always be available. These factors collectively threaten the market's growth potential and underscore the need for robust quality assurance measures.

Covid-19 Impact

The Covid-19 pandemic significantly influenced the predictive presymptomatic testing market. On one hand, disruptions in healthcare systems and diagnostic services delayed testing procedures and reduced patient access to routine screenings. On the other hand, the pandemic underscored the importance of preventive healthcare, spurring interest in genetic testing for early disease detection. As the world transitions to a post-pandemic phase, the market is poised for recovery and growth, driven by renewed focus on preventive health measures.

The genetic testing segment is expected to be the largest during the forecast period

The genetic testing segment is expected to account for the largest market share during the forecast period owing to early diagnosis and intervention for hereditary diseases. Technological advancements and growing awareness about genetic risks have spurred the adoption of these tests. Furthermore, the availability of non-invasive testing methods, like saliva-based genetic testing, has made predictive presymptomatic tests more accessible and affordable.

The next-generation sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the next-generation sequencing (NGS) segment is predicted to witness the highest growth rate due to rapid evolution of genomic medicine and the rise in hereditary disease incidence are factors contributing to this trend. This segment encompasses tests for a variety of conditions, including cancers, cardiovascular diseases, and neurological disorders, all of which benefit from early identification and intervention. The increasing availability of affordable genetic testing options is also expected to drive substantial growth in this segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to well-established healthcare infrastructure, and there is a high demand for genetic testing due to increasing awareness and a growing number of individuals seeking personalized healthcare. Furthermore, the presence of leading research institutions and biotech companies specializing in genetic testing technologies contributes to North America's dominant market share. Government policies promoting genetic literacy and personalized healthcare are also expected to play a significant role in North America's continued market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by advancements in healthcare infrastructure, rising disposable incomes, and an increasing focus on preventive healthcare. Additionally, countries like China and India are experiencing significant growth in genetic research and testing capabilities, driven by both government investments and private sector initiatives. As awareness around hereditary diseases and genetic testing increases, demand for predictive presymptomatic tests is likely to surge in this region, particularly in urban centers with access to cutting-edge healthcare services.

Key players in the market

Some of the key players in Predictive Presymptomatic Testing market include 23andMe, Abbott Laboratories Inc, Quest Diagnostics Inc, Positive Bioscience, Color Genomics, Gene by Gene, Mapmygenome, Myriad Genetics, BioAxis DNA Research Center Private Limited, Direct Laboratory Services LLC, Pathway Genomics Corporation, Ambry Genetics Corporation, Akonni Biosystems, Element Biosciences, Eurofins Scientific and NGeneBio.

Key Developments:

In January 2024, 23andMe Holding Co. announced the launch of Discover23(R), a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit.

In December 2024, Abbott announced it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.

In December 2024, Quest Diagnostics launched health coaching on questhealth.com to help individuals take control of their health. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol.

Types Covered:

  • Genetic Testing
  • Biochemical Testing
  • Molecular Testing
  • Other Types

Indications Covered:

  • Oncology
  • Neurological Disorders
  • Cardiovascular Disorders
  • Endocrine Disorders
  • Inherited Conditions
  • Other Indications

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray Technology
  • Fluorescent In Situ Hybridization (FISH)
  • Other Technologies

Samples Covered:

  • Blood
  • Saliva
  • Tissue Biopsy
  • Other Samples

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Research & Academic Institutions
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Predictive Presymptomatic Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Genetic Testing
    • 5.2.1 Single-Gene Testing
    • 5.2.2 Whole Genome Sequencing
    • 5.2.3 Whole Exome Sequencing
  • 5.3 Biochemical Testing
  • 5.4 Molecular Testing
  • 5.5 Other Types

6 Global Predictive Presymptomatic Testing Market, By Indication

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Neurological Disorders
  • 6.4 Cardiovascular Disorders
  • 6.5 Endocrine Disorders
  • 6.6 Inherited Conditions
  • 6.7 Other Indications

7 Global Predictive Presymptomatic Testing Market, By Technology

  • 7.1 Introduction
  • 7.2 Next-Generation Sequencing (NGS)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Microarray Technology
  • 7.5 Fluorescent In Situ Hybridization (FISH)
  • 7.6 Other Technologies

8 Global Predictive Presymptomatic Testing Market, By Sample

  • 8.1 Introduction
  • 8.2 Blood
  • 8.3 Saliva
  • 8.4 Tissue Biopsy
  • 8.5 Other Samples

9 Global Predictive Presymptomatic Testing Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Laboratories
  • 9.4 Research & Academic Institutions
  • 9.5 Specialty Clinics
  • 9.6 Other End Users

10 Global Predictive Presymptomatic Testing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 23andMe
  • 12.2 Abbott Laboratories Inc.
  • 12.3 Quest Diagnostics Inc.
  • 12.4 Positive Bioscience
  • 12.5 Color Genomics
  • 12.6 Gene by Gene
  • 12.7 Mapmygenome
  • 12.8 Myriad Genetics
  • 12.9 BioAxis DNA Research Center Private Limited
  • 12.10 Direct Laboratory Services LLC
  • 12.11 Pathway Genomics Corporation
  • 12.12 Ambry Genetics Corporation
  • 12.13 Akonni Biosystems
  • 12.14 Element Biosciences
  • 12.15 Eurofins Scientific
  • 12.16 NGeneBio

List of Tables

  • Table 1 Global Predictive Presymptomatic Testing Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Predictive Presymptomatic Testing Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Predictive Presymptomatic Testing Market Outlook, By Genetic Testing (2022-2030) ($MN)
  • Table 4 Global Predictive Presymptomatic Testing Market Outlook, By Single-Gene Testing (2022-2030) ($MN)
  • Table 5 Global Predictive Presymptomatic Testing Market Outlook, By Whole Genome Sequencing (2022-2030) ($MN)
  • Table 6 Global Predictive Presymptomatic Testing Market Outlook, By Whole Exome Sequencing (2022-2030) ($MN)
  • Table 7 Global Predictive Presymptomatic Testing Market Outlook, By Biochemical Testing (2022-2030) ($MN)
  • Table 8 Global Predictive Presymptomatic Testing Market Outlook, By Molecular Testing (2022-2030) ($MN)
  • Table 9 Global Predictive Presymptomatic Testing Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 10 Global Predictive Presymptomatic Testing Market Outlook, By Indication (2022-2030) ($MN)
  • Table 11 Global Predictive Presymptomatic Testing Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 12 Global Predictive Presymptomatic Testing Market Outlook, By Neurological Disorders (2022-2030) ($MN)
  • Table 13 Global Predictive Presymptomatic Testing Market Outlook, By Cardiovascular Disorders (2022-2030) ($MN)
  • Table 14 Global Predictive Presymptomatic Testing Market Outlook, By Endocrine Disorders (2022-2030) ($MN)
  • Table 15 Global Predictive Presymptomatic Testing Market Outlook, By Inherited Conditions (2022-2030) ($MN)
  • Table 16 Global Predictive Presymptomatic Testing Market Outlook, By Other Indications (2022-2030) ($MN)
  • Table 17 Global Predictive Presymptomatic Testing Market Outlook, By Technology (2022-2030) ($MN)
  • Table 18 Global Predictive Presymptomatic Testing Market Outlook, By Next-Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 19 Global Predictive Presymptomatic Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2022-2030) ($MN)
  • Table 20 Global Predictive Presymptomatic Testing Market Outlook, By Microarray Technology (2022-2030) ($MN)
  • Table 21 Global Predictive Presymptomatic Testing Market Outlook, By Fluorescent In Situ Hybridization (FISH) (2022-2030) ($MN)
  • Table 22 Global Predictive Presymptomatic Testing Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 23 Global Predictive Presymptomatic Testing Market Outlook, By Sample (2022-2030) ($MN)
  • Table 24 Global Predictive Presymptomatic Testing Market Outlook, By Blood (2022-2030) ($MN)
  • Table 25 Global Predictive Presymptomatic Testing Market Outlook, By Saliva (2022-2030) ($MN)
  • Table 26 Global Predictive Presymptomatic Testing Market Outlook, By Tissue Biopsy (2022-2030) ($MN)
  • Table 27 Global Predictive Presymptomatic Testing Market Outlook, By Other Samples (2022-2030) ($MN)
  • Table 28 Global Predictive Presymptomatic Testing Market Outlook, By End User (2022-2030) ($MN)
  • Table 29 Global Predictive Presymptomatic Testing Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 30 Global Predictive Presymptomatic Testing Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 31 Global Predictive Presymptomatic Testing Market Outlook, By Research & Academic Institutions (2022-2030) ($MN)
  • Table 32 Global Predictive Presymptomatic Testing Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 33 Global Predictive Presymptomatic Testing Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.